Abstract
The lung clearance index (LCI) measured by the multiple breath washout (MBW) test is sensitive to early lung disease in children with cystic fibrosis. While LCI worsens during the preschool years in cystic fibrosis, there is limited evidence to clarify whether this continues during the early school age years, and whether the trajectory of disease progression as measured by LCI is modifiable.
A cohort of children (healthy and cystic fibrosis) previously studied for 12 months as preschoolers were followed during school age (5–10 years). LCI was measured every 3 months for a period of 24 months using the Exhalyzer D MBW nitrogen washout device. Linear mixed effects regression was used to model changes in LCI over time.
A total of 582 MBW measurements in 48 healthy subjects and 845 measurements in 64 cystic fibrosis subjects were available. The majority of children with cystic fibrosis had elevated LCI at the first preschool and first school age visits (57.8% (37 out of 64)), whereas all but six had normal forced expiratory volume in 1 s (FEV1) values at the first school age visit. During school age years, the course of disease was stable (−0.02 units·year−1 (95% CI −0.14–0.10). LCI measured during preschool years, as well as the rate of LCI change during this time period, were important determinants of LCI and FEV1, at school age.
Preschool LCI was a major determinant of school age LCI; these findings further support that the preschool years are critical for early intervention strategies.
Abstract
Lung clearance index measured during preschool years is a major determinant of school age LCI. These findings further support that the preschool years are critical for early intervention strategies. https://bit.ly/3gZqA7Z
Footnotes
Preliminary results from this study were presented in abstract form at the European Respiratory Congress and the North American Cystic Fibrosis Conference.
This article has supplementary material available from erj.ersjournals.com
This article has an editorial commentary: https://doi.org/10.1183/13993003.00236-2021
Conflict of interest: S. Stanojevic reports grants from CF Canada and US CF Foundation, during the conduct of the study.
Conflict of interest: S.D. Davis has nothing to disclose.
Conflict of interest: L. Perrem has nothing to disclose.
Conflict of interest: M. Shaw has nothing to disclose.
Conflict of interest: G. Retsch-Bogart reports grants from Cystic Fibrosis Foundation, during the conduct of the study.
Conflict of interest: M. Davis has nothing to disclose.
Conflict of interest: R. Jensen has nothing to disclose.
Conflict of interest: C.C. Clem has nothing to disclose.
Conflict of interest: S.M. Isaac has nothing to disclose.
Conflict of interest: J. Guido has nothing to disclose.
Conflict of interest: S. Jara has nothing to disclose.
Conflict of interest: L. France has nothing to disclose.
Conflict of interest: N. McDonald has nothing to disclose.
Conflict of interest: M. Solomon reports grants from Vertex Pharmaceutical and Mylene Pharmaceutical, payment for educational module from Vertex Pharamaceutical, outside the submitted work.
Conflict of interest: N. Sweezey has nothing to disclose.
Conflict of interest: H. Grasemann has nothing to disclose.
Conflict of interest: V. Waters has nothing to disclose.
Conflict of interest: D.B. Sanders has nothing to disclose.
Conflict of interest: F.A. Ratjen reports grants and personal fees for consultancy from Vertex, Calithera, Proteostasis, TranslateBio, Genentech, Bayer and Boehringer Ingelheim, outside the submitted work.
Support statement: This work was supported by the Cystic Fibrosis Foundation (grant: RATJEN14A0) and the National Heart, Lung, and Blood Institute (grant: R01 HL116232). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received September 3, 2020.
- Accepted December 11, 2020.
- Copyright ©ERS 2021. For reproduction rights and permissions contact permissions{at}ersnet.org